Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome

BACKGROUND: Different molecular therapies like the EGFR-inhibiting antibody cetuximab have come into clinical practice. Cetuximab is EMEA-approved for metastatic colorectal cancer and advanced squamous-cell head and neck cancer. Administration is said to be safe and well tolerated with common, usual...

Descripción completa

Detalles Bibliográficos
Autores principales: Knauer, Michael, Haid, Anton, Ammann, Karlheinz, Lang, Alois, Offner, Felix, Türtscher, Martina, Cerkl, Peter, Wenzl, Etienne
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2147013/
https://www.ncbi.nlm.nih.gov/pubmed/17927839
http://dx.doi.org/10.1186/1477-7819-5-114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2147013/
https://www.ncbi.nlm.nih.gov/pubmed/17927839
http://dx.doi.org/10.1186/1477-7819-5-114

Ejemplares similares